On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Finding Ever-Growing Ways to Administer Cannabis Benefits

  • Pivot Pharmaceuticals developing disruptive formulations for cannabis-infused markets
  • Company’s goal is to strengthen dosage predictability and improve product stability
  • Recent acquisitions and planned acquisitions give Pivot vertical position in multi-billion-dollar industries

Despite recent setbacks to efforts seeking broader marijuana legalization in North America (http://cnw.fm/zM2Mc), the tide of social preferences for cannabis availability, even in recreational applications, continues to advance (http://cnw.fm/tT62e). Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is helping to advance efforts to legitimize the drug’s use, both in medicinal and recreational settings, by pursuing ever-increasing methods for consuming cannabis’s derivatives in quantities with predictable outcomes.

“Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” Joseph Borovsky, Pivot’s vice president of product formulation, stated in a recent news release (http://cnw.fm/ji5nV).

The company has filed continuation patents to maintain its impetus in making cannabis available through powdered formulations that can be combined with existing products in the food and beverage market. That includes health and wellness products such as natural sleep-aids, cold medications and vitamins.

On March 6, Pivot Pharmaceuticals announced its acquisition of Thrudermic, LLC, a North Carolina company invested in a transdermal lipid-based nano-dispersion technology to make cannabis formulations available through external delivery. Thrudermic has filed three new patent applications for Pivot related to better formulation and delivery of its product as the company pursues new routes of drug administration.

Pivot’s acquisition of California’s ERS Holdings, LLC in February not only strengthened its options for enhanced health and wellness products; the move gave the company added visibility to beverage makers such as beer companies working to mitigate a potential decline in profits as their customers divert discretionary income from alcohol consumption to cannabis consumption.

“The (Ready-To-Infuse-Cannabis technology) family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks. With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market,” Pivot CEO Patrick Frankham stated in a news release about the acquisition (http://cnw.fm/1xDEK).

The company has also announced plans to acquire Agro-Biotech, a Quebec-based Canadian-licensed cannabis producer (http://cnw.fm/av6uC). Agro-Biotech operates a licensed hydroponic cannabis production facility that can turn out 10,000 kilograms per year, giving Pivot a source for its products as it strives to achieve a stronger vertical position in the industry for cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC).

An agreement between Pivot and Germany’s Solmic Research GmbH gave the company rights to technology designed to give cancer patients relief from vomiting, nausea, neutropenia and anemia during chemotherapy treatment. Those side effects trouble an estimated 70 to 80 percent of chemotherapy patients and often lead to the discontinuation of treatment before the illness has been completely addressed, according to Transparency Market Research (http://cnw.fm/1N15u). Cannabis’s therapeutic abilities are expected to help it grow into a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/F3jWv), and the cancer supportive care products market is expected to reach $29.87 billion by 2021.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722